HENGRUI PHARMA to Inject 285 Million Yuan into Shanghai Ruihongdi

Stock News03-25

HENGRUI PHARMA (01276) has announced the signing of a capital increase agreement on March 25, 2026, with Hengrui Group, Shengdi Biopharmaceutical Fund, Shenzhen Yingtai, and Shanghai Ruihongdi. The agreement will raise Shanghai Ruihongdi's registered capital from approximately 131.6 million yuan to about 230.3 million yuan.

Under the terms of the agreement, HENGRUI PHARMA, Hengrui Group, Shengdi Biopharmaceutical Fund, and Shenzhen Yingtai will collectively contribute a total of 750 million yuan in cash, proportionate to their stakes. HENGRUI PHARMA's investment will amount to 285 million yuan.

Following the completion of the capital increase, the shareholding structure of Shanghai Ruihongdi will remain unchanged, with HENGRUI PHARMA, Hengrui Group, Shengdi Biopharmaceutical Fund, and Shenzhen Yingtai holding 38.0%, 28.0%, 19.0%, and 15.0% equity, respectively.

Shanghai Ruihongdi primarily engages in technology development, consulting, services, and transfer within the pharmaceutical sector. The company possesses an independent core technology platform and strong research and development capabilities, requiring continuous investment to maintain its operational and technological competitiveness.

The capital injection pursuant to the agreement is intended to ensure Shanghai Ruihongdi has sufficient funds for operations, product development, and business expansion, which may potentially enhance the investment returns for HENGRUI PHARMA.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1193333530?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-25 23:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1193333530","market":"sh","top_or_hot":-1,"title":"HENGRUI PHARMA to Inject 285 Million Yuan into Shanghai Ruihongdi","media":"Stock News","content":"<p>HENGRUI PHARMA (01276) has announced the signing of a capital increase agreement on March 25, 2026, with Hengrui Group, Shengdi Biopharmaceutical Fund, Shenzhen Yingtai, and Shanghai Ruihongdi. The agreement will raise Shanghai Ruihongdi's registered capital from approximately 131.6 million yuan to about 230.3 million yuan.</p>\n<p>Under the terms of the agreement, HENGRUI PHARMA, Hengrui Group, Shengdi Biopharmaceutical Fund, and Shenzhen Yingtai will collectively contribute a total of 750 million yuan in cash, proportionate to their stakes. HENGRUI PHARMA's investment will amount to 285 million yuan.</p>\n<p>Following the completion of the capital increase, the shareholding structure of Shanghai Ruihongdi will remain unchanged, with HENGRUI PHARMA, Hengrui Group, Shengdi Biopharmaceutical Fund, and Shenzhen Yingtai holding 38.0%, 28.0%, 19.0%, and 15.0% equity, respectively.</p>\n<p>Shanghai Ruihongdi primarily engages in technology development, consulting, services, and transfer within the pharmaceutical sector. The company possesses an independent core technology platform and strong research and development capabilities, requiring continuous investment to maintain its operational and technological competitiveness.</p>\n<p>The capital injection pursuant to the agreement is intended to ensure Shanghai Ruihongdi has sufficient funds for operations, product development, and business expansion, which may potentially enhance the investment returns for HENGRUI PHARMA.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HENGRUI PHARMA to Inject 285 Million Yuan into Shanghai Ruihongdi</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHENGRUI PHARMA to Inject 285 Million Yuan into Shanghai Ruihongdi\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-25 23:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HENGRUI PHARMA (01276) has announced the signing of a capital increase agreement on March 25, 2026, with Hengrui Group, Shengdi Biopharmaceutical Fund, Shenzhen Yingtai, and Shanghai Ruihongdi. The agreement will raise Shanghai Ruihongdi's registered capital from approximately 131.6 million yuan to about 230.3 million yuan.</p>\n<p>Under the terms of the agreement, HENGRUI PHARMA, Hengrui Group, Shengdi Biopharmaceutical Fund, and Shenzhen Yingtai will collectively contribute a total of 750 million yuan in cash, proportionate to their stakes. HENGRUI PHARMA's investment will amount to 285 million yuan.</p>\n<p>Following the completion of the capital increase, the shareholding structure of Shanghai Ruihongdi will remain unchanged, with HENGRUI PHARMA, Hengrui Group, Shengdi Biopharmaceutical Fund, and Shenzhen Yingtai holding 38.0%, 28.0%, 19.0%, and 15.0% equity, respectively.</p>\n<p>Shanghai Ruihongdi primarily engages in technology development, consulting, services, and transfer within the pharmaceutical sector. The company possesses an independent core technology platform and strong research and development capabilities, requiring continuous investment to maintain its operational and technological competitiveness.</p>\n<p>The capital injection pursuant to the agreement is intended to ensure Shanghai Ruihongdi has sufficient funds for operations, product development, and business expansion, which may potentially enhance the investment returns for HENGRUI PHARMA.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2097828805.USD","symbol_name":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","start_time":0,"source_url":"","article_id":"1193333530","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1193333530","pubTimestamp":1774452481,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"HENGRUI PHARMA (01276) has announced the signing of a capital increase agreement on March 25, 2026, with Hengrui Group, Shengdi Biopharmaceutical Fund, Shenzhen Yingtai, and Shanghai Ruihongdi. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600276":"恒瑞医药","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","BK0028":"国家队","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU1146622755.USD":"安本中国A股股票基金A Acc","LU0359201885.HKD":"BGF CHINA \"A2\" (HKD) ACC","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","BK1191":"制药","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","BK0060":"抗癌","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","LU1655091616.SGD":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","01276":"恒瑞医药","LU2289578879.USD":"ALLIANZ CHINA A OPPORTUNITIES \"AT\" (USD) ACC","LU0359201612.USD":"贝莱德中国基金A2","LU1580142542.USD":"Blackrock Systematic China A-Share Opportunities A2 USD","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","BK0196":"行业龙头","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU1997245177.USD":"安联神洲A股基金","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","BK0239":"医药制造","LU2580892789.USD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (USD) ACC","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","LU1255011170.USD":"JPM CHINA A-SHARE OPPORTUNITIES \"A\" (USD) ACC","LU1781817850.SGD":"Blackrock Systematic China A-Share Opportunities A2 SGD-H","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","BK0183":"MSCI概念","BK0188":"融资融券","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","BK0012":"证金概念","LU2580892862.HKD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (HKD) ACC"},"translate_title":"恒瑞医药将向上海瑞鸿迪注资2.85亿元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600276":1,"01276":1},"content_text":"HENGRUI PHARMA (01276) has announced the signing of a capital increase agreement on March 25, 2026, with Hengrui Group, Shengdi Biopharmaceutical Fund, Shenzhen Yingtai, and Shanghai Ruihongdi. The agreement will raise Shanghai Ruihongdi's registered capital from approximately 131.6 million yuan to about 230.3 million yuan.\nUnder the terms of the agreement, HENGRUI PHARMA, Hengrui Group, Shengdi Biopharmaceutical Fund, and Shenzhen Yingtai will collectively contribute a total of 750 million yuan in cash, proportionate to their stakes. HENGRUI PHARMA's investment will amount to 285 million yuan.\nFollowing the completion of the capital increase, the shareholding structure of Shanghai Ruihongdi will remain unchanged, with HENGRUI PHARMA, Hengrui Group, Shengdi Biopharmaceutical Fund, and Shenzhen Yingtai holding 38.0%, 28.0%, 19.0%, and 15.0% equity, respectively.\nShanghai Ruihongdi primarily engages in technology development, consulting, services, and transfer within the pharmaceutical sector. The company possesses an independent core technology platform and strong research and development capabilities, requiring continuous investment to maintain its operational and technological competitiveness.\nThe capital injection pursuant to the agreement is intended to ensure Shanghai Ruihongdi has sufficient funds for operations, product development, and business expansion, which may potentially enhance the investment returns for HENGRUI PHARMA.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1193333530","isCrawlerRequest":true}